Patients identified as having a Janus kinase inhibitor responder profile were much more likely to respond positively to the class of atopic dermatitis therapies. Scientists have identified gene ...
Marc Goodman Leerink Partners LLC, Research Division. Okay. We're going to get going on our next session. Thanks for joining us. I'm Marc Goodman, one of the biopharma analyst at ...
Abington Heights Sophomore Kale Bonnewell took the polar plunge to support Special Olympics. “I really liked being a part of ...
Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call Transcript March 12, 2026 Nektar Therapeutics beats earnings expectations. Reported EPS is $-1.77756, expectations were $-2.47411. Operator: ...
Shilpa Biologicals and mAbTree Biologics secure US FDA orphan drug designation for breakthrough biologics to treat rare blood cancers: Our Bureau, Bengaluru Friday, March 13, 2026 ...
Objective Biologics for systemic lupus erythematosus (SLE) demonstrate variable treatment responses across trials. We evaluated baseline biomarkers as predictors of response to guide personalised ...
Leerink Global Healthcare Conference 2026 March 10, 2026 9:20 AM EDTCompany ParticipantsPablo Cagnoni - President and Head ...
Total abortion bans effective by early 2023 were associated with a 1.57% monthly birth-rate increase, approximately 1,210 additional births per month and ~14,500 additional births across 13 states in ...
Marks significant milestone for breakthrough biologic to treat rare blood cancersBasel, Switzerland and Raichur, India – 12th March 2026: Shilpa Biologicals, part of the Shilpa Medicare Group, ...
SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) (“SNDL ” or the “Company ”) reported its financial and operational results for the full year and fourth quarter ended December 31, 2025. All financial information ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results